Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30169
Kinetic Spectrophotometric Determination of Ramipril in Commercial Dosage Forms

Authors: Nafisur Rahman, Habibur Rahman, Syed Najmul Hejaz Azmi

Abstract:

This paper presents a simple and sensitive kinetic spectrophotometric method for the determination of ramipril in commercial dosage forms. The method is based on the reaction of the drug with 1-chloro-2,4-dinitrobenzene (CDNB) in dimethylsulfoxide (DMSO) at 100 ± 1ºC. The reaction is followed spectrophotometrically by measuring the rate of change of the absorbance at 420 nm. Fixed-time (ΔA) and equilibrium methods are adopted for constructing the calibration curves. Both the calibration curves were found to be linear over the concentration ranges 20 - 220 μg/ml. The regression analysis of calibration data yielded the linear equations: Δ A = 6.30 × 10-4 + 1.54 × 10-3 C and A = 3.62 × 10-4 + 6.35 × 10-3 C for fixed time (Δ A) and equilibrium methods, respectively. The limits of detection (LOD) for fixed time and equilibrium methods are 1.47 and 1.05 μg/ml, respectively. The method has been successfully applied to the determination of ramipril in commercial dosage forms. Statistical comparison of the results shows that there is no significant difference between the proposed methods and Abdellatef-s spectrophotometric method.

Keywords: Equilibrium method, Fixed-time (ΔA) method, Ramipril, Spectrophotometry.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1329174

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1853

References:


[1] D. N. Franz, "Cardiovascular Drugs (Ed: A. R. Gennaro)," in Remington: The Science and Practice of Pharmacy, 19th ed., Vol. II, Mack Publishing Company, Pennsylvania, 1995, p. 951.
[2] T.G. Warner and M. C. Perry, "Ramipril: a review of its use in the prevention of cardiovascular outcomes," Drugs, vol. 62, pp.1381-1405, 2002.
[3] Royal Pharmaceutical Society, "British Pharmacopoeia," vol. II, H. M. Stationery Office, Royal Pharmaceutical Society, London, UK, 2000, pp.1331-1333.
[4] Z. Zhimeng, V. Andre and N. Len, "Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma," J. Chromatography B., vol. 779, pp. 297-306, 2002.
[5] B. Francesco, M. Patrizia and Q. Fabiasa, "Analysis of ACE inhibtor drugs by high performance liquid chromatography," Il Farmaco, vol. 49, pp. 457-460, 1994.
[6] U. J. Dhorda and N. B. Shetkar, "RP-HPLC determination of ramipril and amlodipine in tablets," Indian Drugs, vol. 36, pp. 638-641, 1999.
[7] S. S. Zarapakar and S. H. Rane, "RP-HPLC determination of ramipril and hydrochlorothiazide in tablets," Indian Drugs, vol. 37, pp. 589-593, 2000.
[8] J. N. Harlikar and A. M. Amlani, "Simultaneous determination of perindopril, indapamide, ramipril, trandapril in pharmaceutical formulations using RP- HPLC," Res. J. Chem. Environ., vol. 7, pp. 59- 62, 2003.
[9] S. Hillaer, K. De Grauwe and W. Van den Bossche, "Simultaneous determination of hydrochlorothiazide and several inhibitors of angiotensin-converting enzyme by capillary electrophoresis," J.Chromatogr. A, vol. 924, pp. 439- 449, 2001.
[10] H. E. Abdellatef, M. M. Ayad and E. A. Taha, "Spectrophotometric and atomic absorption spectrophotometric determination of ramipril and perindopril through ternary complex formation with eosin and Cu (II)," J. Pharm. Biomed. Anal., Vol. 18, pp. 1021-1027, 1999.
[11] M. M. Ayad, A. A. Shalaby, H. E. Abdellatef and M. M. Hosny, "Spectrophotometric and AAS determination of ramipril and enalapril through ternary complex formation," J. Pharm. Biomed. Anal., vol. 28, pp. 311-321, 2002.
[12] J. A. Prieto, R. M. Jimenez and R. M. Alonso, "Square wave voltammetric determination of angiotensin- converting enzyme inhibitors cilazapril, quinapril and ramipril in pharmaceutical formulation," Il Farmaco, vol. 58, pp. 343-350, 2003.
[13] H. Y. Aboul-Enein, R. I. Stefen and J. F. Van Staden, "Analysis of several angiotensin-converting enzyme inhibitors using potentiometric, enantioselective membrane electrodes," Anal. Lett., vol. 32, pp. 623-632, 1999.
[14] H. G. Eckert, G. Muenscher, R. Oekonomopulos, H. Strecker, H. Urbach and H. A. Wissmann, "Radioimmunoassay for the II angiotensinconverting enzyme inhibitor ramipril and its active metabolite," Arzneim.-Forsch, vol. 35, pp.1251-1256, 1985.
[15] H. H. Abdine, F. A. El-Yazbi, R. A. Shaalan and S. M.Blaih, "Direct differential solubility and compensatory- derivative spectrophotometric methods for resolving and subsequently determining binary mixtures of some anti hypertensive drugs," S. T. P. Pharm Sci., vol. 9, pp.587-591, 1999.
[16] H. Salem, "Derivative spectrophotometric determination of two component mixtures," Chin. Pharm. J., vol. 51, pp. 123-142, 1999.
[17] N. Erk, "Ratio-spectra-zero-crossing derivative spectrophotometric determination of certain drugs in two component mixtures," Anal. Lett., vol. 32, pp. 1371-1388, 1999.
[18] S.M. Blaih, H. H. Abdine, F. A. El-Yazbi and R. A. Shaalan, "Spectrophotometric determination of enalapril maleate and ramipril in dosage forms," Spectrosc. Lett., vol. 33, pp. 91-102, 2000.
[19] F. M. Salama, O. I. A. El-Sattar, N. M. El-Aba Sawy and M.M. Fuad, "Spectrophotometric determination of some ACE inhibitors through charge transfer complexes," Al Azhar J. Pharm. Sci., vol. 27, pp. 121- 132, 2001.
[20] A. A. Al-Majed, F. Belal and A. A. Al-Warthan, "Spectrophotometric determination of ramipril (a novel ACE inhibitor) in dosage forms," Spectrosc. Lett., vol. 34, pp. 211-220, 2001.
[21] A. A. Al-Majed and J. Al-Zehouri, "Use of 7- fluoro-4-nitrobenzo-2- oxo-1,3-diazole for the determination of ramipril in tablet and spiked human plasma," Il Farmaco, vol. 56, pp. 291-296, 2001.
[22] N. Rahman, Y. Ahmad and S. N. H. Azmi, "Kinetic spectrophotometric method for the determination of ramipril in pharmaceutical formulations," A. A. P. S. PharmSciTech., vol.6, pp. 543-551, 2005.
[23] J. Ermer, "Validation in pharmaceutical analysis. Part I: An integrated approach.," J. Pharm. Biomed. Anal., vol. 24, pp.755-767, 2001.
[24] H. E. Bent and C. L. French, "The structure of ferric thiocyanate and its dissociation in aqueous solution," J. Am. Chem. Soc., vol. 63, pp. 568- 572, 1941.
[25] E. Buncell, A. R. Norris and K. E. Russell, "The interaction of aromatic nitro compounds with bases," Q. Rev. Chem. Soc., vol. 22, pp.123-125, 1968.
[26] E. Buncell, A. R. Norris and K. E. Russell, "The interaction of aromatic nitro compounds with bases," Q. Rev. Chem. Soc., vol. 22, pp.123-125, 1968.
[27] M. J. Strauss, "Anionic sigma complexes," Chem. Rev., vol. 70, pp. 667-712, 1970.
[28] C. Hartmann, J. Smeyers-Verbeke, W. Pinninckx, Y.V. Heyden, P. Vankeerberghen and D. L. Massart, "Reappraisal of hypothesis testing for method validation: detection systematic error by comparing the means of two methods or of two laboratories," Anal. Chem., vol. 67, pp.4491-4499, 1995.
[29] Canada Health Protection Branch, "Drugs Directorate Guidelines, Acceptable methods", Ministry of National Health and Welfare, Draft, Ottawa, Canada , 1992.